New Tobramycin Derivatives Show Improved Antibacterial Activity
Author Information
Author(s): Shapovalova Kseniya S., Zatonsky Georgy V., Razumova Elizaveta A., Ipatova Daria A., Lukianov Dmitrii A., Sergiev Petr V., Grammatikova Natalia E., Tikhomirov Alexander S., Shchekotikhin Andrey E.
Primary Institution: Gause Institute of New Antibiotics
Hypothesis
Can modifications at the 6″-position of tobramycin enhance its antibacterial properties against resistant strains?
Conclusion
The new tobramycin derivatives are more effective against resistant P. aeruginosa strains and have reduced cytotoxicity compared to the original tobramycin.
Supporting Evidence
- The new derivatives showed a resistance index of 4–16 against resistant P. aeruginosa strains, compared to >256 for tobramycin.
- All new compounds exhibited reduced cytotoxicity for HEK293T cells compared to tobramycin.
- The modifications did not alter the mechanism of action, which involves inducing translation errors in bacterial cells.
Takeaway
Scientists created new versions of tobramycin that work better against tough bacteria and are less harmful to human cells.
Methodology
The study involved synthesizing new tobramycin derivatives and testing their antibacterial activity against various bacterial strains.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website